Analysis of the primary BL specimens showed cytoplasmic TPM2 expression in the tumor cells of 8/11 (73%) NR but only 5/36 (14%) R patients, showing a significant association between this marker and resistance to therapy (p = 0.0002 by Fisher Exact test) (Fig. 5D and Supplementary Fig. 6D). Here, TPM2 is linked to Burkitt lymphoma.